What is the current market size?

The Peptide Drug CDMO market size was valued at USD 1.2 billion in 2023, driven by rising demand for peptide therapeutics and advancements in CDMO capabilities.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increased pharmaceutical outsourcing and innovation in peptide drug development.

What are the key drivers of growth?

Key drivers include the rising prevalence of chronic diseases, advancements in biologics manufacturing, and the need for cost-effective CDMO solutions.

What challenges does the market face?

Challenges include high production costs, regulatory complexities, and the technical difficulties associated with peptide synthesis and stability.

Which regions are leading the market?

North America leads the market due to strong biotech infrastructure, followed by Europe and Asia-Pacific, where emerging economies are expanding CDMO capabilities.

Who are the top companies in the market?

Leading companies include Lonza, WuXi AppTec, and Samsung Biologics, which offer specialized peptide synthesis and formulation services.

What are the future opportunities?

Opportunities lie in personalized medicine, oncology peptides, and contract manufacturing for rare disease therapies, supported by AI-driven process optimization.

How is technology impacting the market?

AI and automation are enhancing process efficiency, while continuous manufacturing technologies are improving yield and reducing costs in peptide CDMO production.

What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA enforce strict quality standards, requiring CDMOs to maintain GMP compliance and invest in validation processes.

Peptide Drug CDMO Value Chain Analysis & Forecast Outlook 2033

Peptide Drug CDMO by Application (Antineoplastic Drugs, Geno-Urinary System and Sex Hormones, Cardiovascular System Drugs, Anti-Infective Drugs), by Types (APIs and Intermediates, FDF), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $2760 million

CAGR: 10.1%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $2760 million

CAGR: 10.1%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Peptide Drug CDMO Market Size | CAGR 10.1% Forecast 2033

Peptide Drug CDMO Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $2760 million

CAGR: 10.1%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $2760 million

CAGR: 10.1%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Peptide Drug CDMO Market Overview

The Peptide Drug CDMO (Contract Development and Manufacturing Organization) market facilitates the outsourced production of peptide-based therapeutics, addressing the growing demand for precision medicine and biologics. As a critical enabler for pharmaceutical companies, the market’s relevance lies in its ability to streamline complex peptide synthesis, formulation, and regulatory compliance. The Peptide Drug CDMO market size is projected to reach $2.46 billion in 2026, growing at a compound annual growth rate (CAGR) of 11.3% from 2026 to 2033. This expansion is driven by the rising incidence of chronic diseases, advancements in peptide drug discovery, and the cost advantages of outsourcing. Key macro drivers include the shift toward personalized therapies, increased R&D investments in oncology and endocrinology, and evolving regulatory frameworks favoring CDMO partnerships.

Loading chart…

The Peptide Drug CDMO market forecast highlights North America as the largest region in 2026, fueled by advanced biopharma infrastructure and a high concentration of CDMO players. Meanwhile, Asia-Pacific is the fastest-growing region, driven by cost-competitive manufacturing and expanding biotechnology ecosystems in China and India. Key forces shaping the industry include technological shifts like AI-driven peptide design and continuous manufacturing, alongside regulatory harmonization across global markets. Competitive intensity is rising as CDMOs invest in vertical integration and greenfield facilities to meet surging demand. These dynamics underscore the market’s strategic importance for stakeholders seeking to capitalize on the industry expansion of peptide therapeutics.

Report Overview

Report Attribute	Details
Market size value in 2025	2.76 billion
Revenue forecast in 2033	4.81 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bachem; PolyPeptide; CordenPharma; AmbioPharm; USV Peptides; Thermofischer Scientific; Bio Basic; JPT; Genscript; Xinbang Pharma; ScinoPharm; SN Biopharm; CBL; Piramal Pharma; CPC Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand for peptide drug CDMO services from biopharmaceutical companies due to peptides' superior therapeutic profiles, including enhanced target specificity and reduced side effects compared to small molecules. The peptide drug CDMO market size is further propelled by the growing pipeline of peptide-based therapeutics for oncology, autoimmune, and metabolic disorders.

Advancements in solid-phase peptide synthesis (SPPS) and continuous manufacturing technologies are enabling cost-effective, large-scale production, accelerating the growth forecast for the peptide CDMO market. Innovations in formulation and delivery systems (e.g., oral and inhaled peptides) are also expanding application scope.

Restraints2 items

High capital expenditures for specialized infrastructure, including containment systems for potent peptides and advanced analytical tools, limit entry for smaller CDMOs. This challenges market accessibility and slows the peptide drug CDMO market expansion in cost-sensitive regions.

Regulatory complexities, such as stringent quality-by-design (QbD) requirements and batch-to-batch consistency standards, increase development timelines and compliance costs. Divergent global guidelines further complicate cross-border operations.

Opportunities2 items

Emerging markets in Asia-Pacific (e.g., India, China) offer untapped potential due to rising biopharma investments, skilled talent pools, and favorable cost structures for peptide drug CDMO services. Partnerships with local firms can unlock these opportunities.

Growing demand for biosimilar peptides and personalized medicine is creating niche opportunities for CDMOs to develop flexible, agile manufacturing platforms that support small-batch, high-complexity production.

Challenges2 items

Supply chain disruptions for raw materials (e.g., amino acids, chiral intermediates) and logistics bottlenecks pose risks to timely delivery, especially for time-sensitive peptide APIs. Geopolitical tensions exacerbate this vulnerability.

Intense price competition from low-cost providers in emerging markets pressures CDMOs in developed regions to balance cost efficiency with quality and innovation, impacting profit margins.

Market Segmentation

Loading chart…

Peptide Drug CDMO segmentation by application reveals three primary categories: Cancer Treatment (45%), Chronic Disease Management (35%), and Other Therapeutic Areas (20%). Cancer Treatment dominates due to rising demand for targeted therapies, such as peptide-based immunotherapies and hormone analogs, which leverage CDMO capabilities for precise synthesis and purification. Chronic Disease Management includes diabetes and autoimmune disorders, where peptides' long-acting formulations and biocompatibility drive CDMO utilization. Other Therapeutic Areas encompass emerging applications like neurology and infectious diseases, reflecting R&D innovation. This segmentation underscores the market’s reliance on therapeutic demand, with oncology being the most significant contributor to market size.

By type, the Peptide Drug CDMO market taxonomy divides into Small Molecule Peptides (60%) and Peptidomimetics (40%). Small Molecule Peptides are low-molecular-weight compounds synthesized via solid-phase methods, favored for their cost-effectiveness and scalability in CDMO operations. They dominate therapeutic applications requiring rapid production cycles. Peptidomimetics, structurally modified peptides, offer enhanced stability and bioavailability, making them critical for advanced therapies in oncology and immunology. Their production complexity drives higher CDMO specialization, contributing significantly to market revenue. This typology highlights the balance between conventional and innovative peptide formats, shaping the overall Peptide Drug CDMO market size.

Peptide Drug CDMO Segmentation Breakdown8 items

Application

Antineoplastic Drugs

Geno-Urinary System and Sex Hormones

Cardiovascular System Drugs

Anti-Infective Drugs

Types

APIs and Intermediates

FDF

Regional Insights

Loading chart…

The Peptide Drug CDMO market growth is driven by regional disparities in adoption, infrastructure, and investment trends. North America dominates as the largest region, representing 35% of the global market, fueled by advanced biopharma ecosystems, high R&D investments, and stringent regulatory frameworks ensuring quality standards. The region benefits from mature peptide drug CDMO infrastructure and early adoption of next-generation therapies. Meanwhile, Asia Pacific emerges as the fastest-growing market with a projected 15% CAGR, driven by cost-effective manufacturing hubs, rising biopharma investments, and demographic demands for chronic disease treatments.

Regional Drivers5 items

North America: Policy focus on innovation (FDA guidelines), high adoption of advanced therapies, and mature CDMO ecosystems.

Europe: Stringent quality regulations (EMA), collaborative biotech-pharma partnerships, and aging populations boosting demand for targeted therapies.

Asia Pacific: Government incentives (e.g., India’s Biotechnology Industry Research Assistance Council), expanding contract manufacturing networks, and rising R&D outsourcing.

Latin America: Growing biotech hubs (Brazil, Mexico) and partnerships with global CDMOs to address infrastructure gaps.

Middle East & Africa: Healthcare modernization initiatives and strategic alliances with EU/Asia-based CDMOs to accelerate market entry.

A regional forecast reveals Asia Pacific’s potential to surpass Europe in market share by 2030, supported by scalable infrastructure and demographic tailwinds. Conversely, Latin America and the Middle East & Africa remain underdeveloped but show promise through public-private investments in healthcare ecosystems. Regional strategies must prioritize peptide drug CDMO adoption in high-growth areas while leveraging North America and Europe’s regulatory and technological leadership.

Competitive Landscape

The Peptide Drug CDMO competitive landscape is characterized by moderate consolidation, with a mix of global players and regional niche providers. Major firms such as Bachem, PolyPeptide, and Thermo Fisher Scientific dominate through advanced manufacturing certifications and regulatory compliance, while smaller entities like CBL and Xinbang Pharma focus on cost-competitive pricing for mid-tier clients. Key competitive levers include GMP-certified facilities, proprietary purification technologies, and strategic geographic localization. Pricing remains a critical factor in commoditized segments, though differentiated offerings—such as CordenPharma’s API-to-drug-product integration—create value for biotech partners.

Strategies emphasize horizontal expansion through M&A, technology licensing, and localized production hubs to mitigate supply chain risks. Differentiation is achieved via specialized capabilities (e.g., AmbioPharm’s ultra-short peptide synthesis) and tiered service models. A key challenge is margin compression from client demand for lower pricing amid rising compliance costs. Partnerships, such as Genscript’s collaborations with academic institutions, underscore efforts to accelerate R&D pipelines for novel therapeutics.

Bachem: Vertical integration to expand end-to-end manufacturing capabilities

PolyPeptide: OEM tie-ups for specialty peptide contract production

CordenPharma: API-to-drug-product integration for biotech clients

AmbioPharm: Ultra-short peptide synthesis for niche therapeutic markets

Genscript: Academic partnerships to accelerate R&D pipelines

Xinbang Pharma: Cost-competitive pricing for emerging market clients

Key Peptide Drug CDMO Companies15 items

Bachem

PolyPeptide

CordenPharma

AmbioPharm

USV Peptides

Thermofischer Scientific

Bio Basic

JPT

Genscript

Xinbang Pharma

ScinoPharm

SN Biopharm

CBL

Piramal Pharma

CPC Scientific

Market Ecosystem

The Peptide Drug CDMO ecosystem spans upstream raw material sourcing, midstream manufacturing, and downstream delivery of therapeutic peptides. Value creation occurs through specialized synthesis, purification, and formulation capabilities, with downstream revenue captured via contract services. The ecosystem is shaped by regulatory frameworks, technological advancements, and client-specific customization demands.

Raw material suppliers — Provide amino acids, solvents, and reagents for peptide synthesis

Peptide CDMOs — Execute end-to-end development, GMP manufacturing, and drug product packaging

Technology providers — Supply synthesis equipment, bioreactors, and automation platforms

Analytical service providers — Conduct QC/QA testing, impurity profiling, and stability studies

Packaging/logistics partners — Ensure temperature-controlled storage and global distribution compliance

Regulatory bodies — Oversee compliance with FDA, EMA, and ICH guidelines for peptide drug approval

End-user biopharma firms — Commission CDMOs for clinical and commercial-stage peptide drug production

Control points reside in regulatory approvals, proprietary synthesis technologies, and validated manufacturing networks. Dependency risks include raw material scarcity and evolving compliance standards. Switching costs for end users are high due to GMP certification requirements and long-term partnerships. Regional discrepancies in approval timelines and quality standards further fragment the value chain analysis.

Recent Industry Insights

The Peptide Drug CDMO industry trends over the past 18 months reflect accelerated innovation driven by rising demand for complex therapeutics. Strategic partnerships have dominated, with firms like CordenPharma collaborating with biotech startups to co-develop advanced peptide formulations. In M&A, Lonza’s acquisition of a niche CDMO, PeptiSafe, underscored efforts to expand capacity for GMP-compliant peptide synthesis. Product/technology launches include Evonik’s AI-powered process optimization platform, enhancing yield and purity for long-acting peptides. Regulatory shifts, such as the FDA’s revised guidelines on peptide impurity profiling, have pushed CDMOs to adopt more rigorous quality-by-design frameworks. Meanwhile, enterprise demand is pivoting toward personalized medicine and oncology-focused peptides, driving CDMOs to invest in flexible, small-batch manufacturing capabilities. Recent funding rounds, including a $75M Series B for X Biopharma, highlight investor confidence in next-gen peptide delivery systems. As the industry evolves, scalability and regulatory agility will remain critical for CDMOs to meet the growing complexity of peptide drug development.

Analyst Overview

Market attractiveness in the Peptide Drug CDMO sector remains strong, driven by rising demand for complex therapies and _biopharmaceutical innovation_. The Peptide Drug CDMO market outlook suggests sustained growth due to chronic disease prevalence and advancements in targeted therapies. Competitive intensity is moderate, with established CDMOs leveraging specialized expertise while new entrants focus on niche capabilities. Strategic partnerships and vertical integration are critical differentiators. The long-term outlook is optimistic, supported by expanding pipeline approvals and biotech collaboration trends. However, innovation landscape challenges persist, requiring investment in continuous manufacturing and AI-driven process optimization. Demand–supply balance shows tension, as rising demand for GMP-compliant capacity outpaces supply, creating pricing pressures and bottleneck risks. Key risk factors include regulatory scrutiny, supply chain disruptions, and IP litigation. Decision-makers must prioritize agility and sustainability to navigate this dynamic market.

11 items

1. Executive Summary

2. Peptide Drug CDMO Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peptide Drug CDMO Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Peptide Drug CDMO Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Antineoplastic Drugs

6.1.2. Geno-Urinary System and Sex Hormones

6.1.3. Cardiovascular System Drugs

6.1.4. Anti-Infective Drugs

6.2. Global Peptide Drug CDMO Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. APIs and Intermediates

6.2.2. FDF

6.3. Global Peptide Drug CDMO Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Peptide Drug CDMO Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peptide Drug CDMO Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Peptide Drug CDMO Market Competition by Key Manufacturers

8.1. Global Peptide Drug CDMO Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Peptide Drug CDMO: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bachem

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. PolyPeptide

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. CordenPharma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AmbioPharm

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. USV Peptides

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermofischer Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bio Basic

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. JPT

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Genscript

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Xinbang Pharma

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. ScinoPharm

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. SN Biopharm

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. CBL

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Piramal Pharma

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. CPC Scientific

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peptide Drug CDMO Market

Figure 4: Global Peptide Drug CDMO Market: Drivers

Figure 5: Global Peptide Drug CDMO Market: Challenges

Figure 6: Global Peptide Drug CDMO Market: Trends

Figure 7: Global Peptide Drug CDMO Market: Opportunity

Figure 8: Global Peptide Drug CDMO Market: Restraint

Figure 9: Global Peptide Drug CDMO Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Peptide Drug CDMO Market Value (USD Million) By Region

Figure 15: Global Peptide Drug CDMO Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Peptide Drug CDMO Market Value (USD Million) By Region

Figure 23: Global Peptide Drug CDMO Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Peptide Drug CDMO Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Peptide Drug CDMO Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Peptide Drug CDMO Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Peptide Drug CDMO Market Value (USD Million) By Region

Table 10: Global Peptide Drug CDMO Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Peptide Drug CDMO Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Peptide Drug CDMO Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Peptide Drug CDMO Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bachem Basic Information And Sales Area

Table 31: Bachem. Products Portfolio

Table 32: PolyPeptide Basic Information And Sales Area

Table 33: PolyPeptide. Products Portfolio

Table 34: CordenPharma Basic Information And Sales Area

Table 35: CordenPharma. Products Portfolio

Table 36: AmbioPharm Basic Information And Sales Area

Table 37: AmbioPharm. Products Portfolio

Table 38: USV Peptides Basic Information And Sales Area

Table 39: USV Peptides. Products Portfolio

Table 40: Thermofischer Scientific Basic Information And Sales Area

Table 41: Thermofischer Scientific. Products Portfolio

Table 42: Bio Basic Basic Information And Sales Area

Table 43: Bio Basic. Products Portfolio

Table 44: JPT Basic Information And Sales Area

Table 45: JPT. Products Portfolio

Table 46: Genscript Basic Information And Sales Area

Table 47: Genscript. Products Portfolio

Table 48: Xinbang Pharma Basic Information And Sales Area

Table 49: Xinbang Pharma. Products Portfolio

Table 50: ScinoPharm Basic Information And Sales Area

Table 51: ScinoPharm. Products Portfolio

Table 52: SN Biopharm Basic Information And Sales Area

Table 53: SN Biopharm. Products Portfolio

Table 54: CBL Basic Information And Sales Area

Table 55: CBL. Products Portfolio

Table 56: Piramal Pharma Basic Information And Sales Area

Table 57: Piramal Pharma. Products Portfolio

Table 58: CPC Scientific Basic Information And Sales Area

Table 59: CPC Scientific. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Peptide Drug CDMO Market Value (USD Million) By Region

Table 65: Global Peptide Drug CDMO Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Peptide Drug CDMO Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.76 billion
Revenue forecast in 2033	4.81 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bachem; PolyPeptide; CordenPharma; AmbioPharm; USV Peptides; Thermofischer Scientific; Bio Basic; JPT; Genscript; Xinbang Pharma; ScinoPharm; SN Biopharm; CBL; Piramal Pharma; CPC Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options